NovoCure Limited
NVCR
$15.58
-$0.25-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3.98% | 3.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.98% | 3.15% | |||
| Cost of Revenue | -8.09% | 2.07% | |||
| Gross Profit | 7.54% | 3.48% | |||
| SG&A Expenses | 39.99% | 5.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.46% | 1.75% | |||
| Operating Income | -94.29% | 4.51% | |||
| Income Before Tax | -155.76% | 5.03% | |||
| Income Tax Expenses | 19.27% | -15.60% | |||
| Earnings from Continuing Operations | -115.64% | 8.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -115.64% | 8.40% | |||
| EBIT | -94.29% | 4.51% | |||
| EBITDA | -104.55% | 3.63% | |||
| EPS Basic | -115.19% | 8.87% | |||
| Normalized Basic EPS | -276.32% | 10.17% | |||
| EPS Diluted | -115.23% | 8.90% | |||
| Normalized Diluted EPS | -276.32% | 10.17% | |||
| Average Basic Shares Outstanding | 0.21% | 0.51% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||